title: Antifibrotic effects of ω-3 fatty acids in the heart: one possible treatment for diastolic heart failure.
abstract: Half of heart failure patients have diastolic heart failure, which has no effective treatments. Several studies indicate a role for ω-3 polyunsaturated fatty acids (PUFAs) in heart failure. Recent studies suggest that ω-3 PUFAs inhibit cardiac fibrosis and attenuate diastolic dysfunction. This opens up possible new avenues for treatment of diastolic heart failure. In this review, we focus on the antifibrotic effects of ω-3 PUFAs in heart and the underlying cellular and molecular mechanisms.
authors.affiliation: Aurora Sinai Medical Center, Milwaukee, WI 53201, USA. dajun.wang@aurora.org
authors.forename: Dajun
authors.initials: D
authors.lastname: Wang
authors.forename: John
authors.initials: J
authors.lastname: O'Horo
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000378:metabolism; D017869:Cyclic GMP-Dependent Protein Kinases / Q000378:metabolism; D003971:Diastole / Q000187:drug effects; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005355:Fibrosis; D054144:Heart Failure, Diastolic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D009206:Myocardium / Q000378:metabolism / Q000473:pathology*; D009569:Nitric Oxide / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
chemical_list: D002317:Cardiovascular Agents; D015525:Fatty Acids, Omega-3; D053773:Transforming Growth Factor beta1; D009569:Nitric Oxide; D017869:Cyclic GMP-Dependent Protein Kinases; D006152:Cyclic GMP